GenSight Biologics (SIGHT) H1 2025 earnings summary

Executive summary

• Operating income fell sharply to €0.04M from €1.7M year-over-year, mainly due to lower research tax credit and the impact of rebate obligations on ATU revenues.

• Net loss increased to €7.0M from €5.8M year-over-year, with loss per share at €(0.05) versus €(0.07).

• R&D, sales & marketing, and G&A expenses all declined, reflecting cost control and focus on manufacturing transfer and regulatory milestones.

Financial highlights

• Revenue recognized solely from changes in refund liability and rebate obligations; no new product sales.

• R&D expenses dropped 31.8% to €4.3M; G&A fell 10% to €2.3M; sales & marketing down 12.8% to €0.2M.

• Cash and cash equivalents at €0.3M as of June 30, 2025, down from €2.5M at year-end 2024.

• Net cash used in operations was €2.5M, with €0.3M net cash from financing activities in H1 2025.

Outlook and guidance

• French Early Access Program (AAC) for GS010 expected to open in Q4 2025, potentially extending cash runway to May 2026.

• Additional financing may be needed if regulatory approval for the dose-ranging study is delayed.

• Medium-term funding strategy includes non-dilutive (EAP, licensing) and dilutive (equity) sources.